Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson’s Disease
- 31 August 2026
- journal article
- review article
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 28 (1) , 51
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Dysfunctional Ubiquitin-Proteasome System and Consequences: Disease Mechanism2026
- Ambroxol as a Treatment for Parkinson Disease DementiaJAMA Neurology, 2025
- Chaperone-Mediated Autophagy in Health and Disease2025
- α‐Synuclein in Parkinson's Disease: From Bench to BedsideMedicinal Research Reviews, 2024
- Autophagy–lysosomal-associated neuronal death in neurodegenerative diseaseActa Neuropathologica, 2024
- Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategiesCellular and Molecular Life Sciences, 2024
- Targeting lysosomal quality control as a therapeutic strategy against aging and diseasesMedicinal Research Reviews, 2024
- α‐Synuclein phase separation and amyloid aggregation are modulated by C‐terminal truncationsFEBS Letters, 2022
- Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as BiomarkersMovement Disorders, 2022
- α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body diseaseActa Neuropathologica, 2019